Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.41 |
| ▸ | SDCBP | O00560 | 1/20 | 0.40 |
| ▸ | SDC2 | P34741 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248327 | 0.92 | FPR3 (0.43) | HDAC1NAMPTBRD4CTSSCTSK | |
| SCHEMBL7248486 | 0.83 | BRD4 (0.44) | HDAC1NAMPTBRD4CTSSAKT1 | |
| SCHEMBL7242751 | 0.82 | BRD4 (0.42) | HDAC1NAMPTBRD4AKT1MAPT | |
| SCHEMBL5208188 | 0.81 | HDAC1 (0.51) | HDAC1NAMPTBRD4CACNA1GSDCBP | |
| SCHEMBL5205406 | 0.78 | HDAC1 (0.46) | HDAC1NAMPTBRD4CACNA1GSDCBP | |
| SCHEMBL1691047 | 0.77 | HDAC1 (0.67) | HDAC1NAMPTSDCBPSDC2CTSS | |
| SCHEMBL5204889 | 0.76 | HDAC1 (0.47) | HDAC1NAMPTSDCBPSDC2CTSS | |
| SCHEMBL7249520 | 0.76 | NAMPT (0.53) | HDAC1NAMPTBRD4MAPTTDP1 | |
| SCHEMBL5208000 | 0.72 | HDAC1 (0.44) | HDAC1SDCBPSDC2AKT1TDP1 | |
| SCHEMBL2807761 | 0.71 | NAMPT (0.51) | HDAC1NAMPTBRD4CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149027-A1 | 1,5-benzodiazepine compounds, their production and use | OI SATORU (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1123928-A1 | 1,5-BENZODIAZEPINE COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND MEDICINE | Takeda Chemical Industries, Ltd. (JP) | 2001-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149027-A1 | 1,5-benzodiazepine compounds, their production and use | GABRA1, GABRA5, CNR1 | HDAC1 402/4885NAMPT 4081/4885BRD4 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.